215 related articles for article (PubMed ID: 34990728)
1. Roflupram attenuates α-synuclein-induced cytotoxicity and promotes the mitochondrial translocation of Parkin in SH-SY5Y cells overexpressing A53T mutant α-synuclein.
Zhong J; Li M; Xu J; Dong W; Qin Y; Qiu S; Li X; Wang H
Toxicol Appl Pharmacol; 2022 Feb; 436():115859. PubMed ID: 34990728
[TBL] [Abstract][Full Text] [Related]
2. Roflupram protects against rotenone-induced neurotoxicity and facilitates α-synuclein degradation in Parkinson's disease models.
Dong WL; Zhong JH; Chen YQ; Xie JF; Qin YY; Xu JP; Cai NB; Li MF; Liu L; Wang HT
Acta Pharmacol Sin; 2021 Dec; 42(12):1991-2003. PubMed ID: 34531546
[TBL] [Abstract][Full Text] [Related]
3. Phosphorylation of Parkin at serine 131 by p38 MAPK promotes mitochondrial dysfunction and neuronal death in mutant A53T α-synuclein model of Parkinson's disease.
Chen J; Ren Y; Gui C; Zhao M; Wu X; Mao K; Li W; Zou F
Cell Death Dis; 2018 Jun; 9(6):700. PubMed ID: 29899409
[TBL] [Abstract][Full Text] [Related]
4. p38 MAPK-DRP1 signaling is involved in mitochondrial dysfunction and cell death in mutant A53T α-synuclein model of Parkinson's disease.
Gui C; Ren Y; Chen J; Wu X; Mao K; Li H; Yu H; Zou F; Li W
Toxicol Appl Pharmacol; 2020 Feb; 388():114874. PubMed ID: 31881179
[TBL] [Abstract][Full Text] [Related]
5. α-mangostin derivative 4e as a PDE4 inhibitor promote proteasomal degradation of alpha-synuclein in Parkinson's disease models through PKA activation.
Chen JY; Zhu Q; Cai CZ; Luo HB; Lu JH
Phytomedicine; 2022 Jul; 101():154125. PubMed ID: 35525236
[TBL] [Abstract][Full Text] [Related]
6. Involvement of mortalin/GRP75/mthsp70 in the mitochondrial impairments induced by A53T mutant α-synuclein.
Liu FT; Chen Y; Yang YJ; Yang L; Yu M; Zhao J; Wu JJ; Huang F; Liu W; Ding ZT; Wang J
Brain Res; 2015 Apr; 1604():52-61. PubMed ID: 25665531
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotective effects of extract of Acanthopanax senticosus harms on SH-SY5Y cells overexpressing wild-type or A53T mutant α-synuclein.
Li XZ; Zhang SN; Wang KX; Liu HY; Yang ZM; Liu SM; Lu F
Phytomedicine; 2014 Apr; 21(5):704-11. PubMed ID: 24252343
[TBL] [Abstract][Full Text] [Related]
8. α-Synuclein Regulates Iron Homeostasis via Preventing Parkin-Mediated DMT1 Ubiquitylation in Parkinson's Disease Models.
Bi M; Du X; Jiao Q; Liu Z; Jiang H
ACS Chem Neurosci; 2020 Jun; 11(11):1682-1691. PubMed ID: 32379419
[TBL] [Abstract][Full Text] [Related]
9. Manganese-induced alpha-synuclein overexpression aggravates mitochondrial damage by repressing PINK1/Parkin-mediated mitophagy.
Liu ZQ; Liu K; Liu ZF; Cong L; Lei MY; Ma Z; Li J; Deng Y; Liu W; Xu B
Food Chem Toxicol; 2021 Jun; 152():112213. PubMed ID: 33862121
[TBL] [Abstract][Full Text] [Related]
10. Roflupram, a Phosphodiesterase 4 Inhibitior, Suppresses Inflammasome Activation through Autophagy in Microglial Cells.
You T; Cheng Y; Zhong J; Bi B; Zeng B; Zheng W; Wang H; Xu J
ACS Chem Neurosci; 2017 Nov; 8(11):2381-2392. PubMed ID: 28605578
[TBL] [Abstract][Full Text] [Related]
11. Roflupram, a novel phosphodiesterase 4 inhibitor, inhibits lipopolysaccharide-induced neuroinflammatory responses through activation of the AMPK/Sirt1 pathway.
Li D; Xu J; Qin Y; Cai N; Cheng Y; Wang H
Int Immunopharmacol; 2021 Jan; 90():107176. PubMed ID: 33243606
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of phosphodiesterase 4 by FCPR16 protects SH-SY5Y cells against MPP
Zhong J; Yu H; Huang C; Zhong Q; Chen Y; Xie J; Zhou Z; Xu J; Wang H
Redox Biol; 2018 Jun; 16():47-58. PubMed ID: 29475134
[TBL] [Abstract][Full Text] [Related]
13. The interplay between parkin and alpha-synuclein; possible implications for the pathogenesis of Parkinson's disease.
Jęśko H; Lenkiewicz AM; Wilkaniec A; Adamczyk A
Acta Neurobiol Exp (Wars); 2019; 79(3):276-289. PubMed ID: 31587020
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotection of α-synuclein under acute and chronic rotenone and maneb treatment is abolished by its familial Parkinson's disease mutations A30P, A53T and E46K.
Choong CJ; Say YH
Neurotoxicology; 2011 Dec; 32(6):857-63. PubMed ID: 21658409
[TBL] [Abstract][Full Text] [Related]
15. Interaction of α-synuclein and Parkin in iron toxicity on SH-SY5Y cells: implications in the pathogenesis of Parkinson's disease.
Ganguly U; Banerjee A; Chakrabarti SS; Kaur U; Sen O; Cappai R; Chakrabarti S
Biochem J; 2020 Mar; 477(6):1109-1122. PubMed ID: 32108853
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of wild-type and A53T mutant isoform of alpha-synuclein on the mitochondrial proteome of differentiated SH-SY5Y cells.
Pennington K; Peng J; Hung CC; Banks RE; Robinson PA
J Proteome Res; 2010 May; 9(5):2390-401. PubMed ID: 20334438
[TBL] [Abstract][Full Text] [Related]
17. Roflupram exerts neuroprotection via activation of CREB/PGC-1α signalling in experimental models of Parkinson's disease.
Zhong J; Dong W; Qin Y; Xie J; Xiao J; Xu J; Wang H
Br J Pharmacol; 2020 May; 177(10):2333-2350. PubMed ID: 31972868
[TBL] [Abstract][Full Text] [Related]
18. Linking alpha-synuclein phosphorylation to reactive oxygen species formation and mitochondrial dysfunction in SH-SY5Y cells.
Perfeito R; Lázaro DF; Outeiro TF; Rego AC
Mol Cell Neurosci; 2014 Sep; 62():51-9. PubMed ID: 25109238
[TBL] [Abstract][Full Text] [Related]
19. Suppression of MAPK attenuates neuronal cell death induced by activated glia-conditioned medium in alpha-synuclein overexpressing SH-SY5Y cells.
Yshii LM; Denadai-Souza A; Vasconcelos AR; Avellar MC; Scavone C
J Neuroinflammation; 2015 Oct; 12():193. PubMed ID: 26502720
[TBL] [Abstract][Full Text] [Related]
20. Lycorine, a natural alkaloid, promotes the degradation of alpha-synuclein via PKA-mediated UPS activation in transgenic Parkinson's disease models.
Zhu Q; Zhuang XX; Chen JY; Yuan NN; Chen Y; Cai CZ; Tan JQ; Su HX; Lu JH
Phytomedicine; 2021 Jul; 87():153578. PubMed ID: 34038839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
